drugset
drugset / Trial / NCT03908957

to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers

NCT03908957 ↗

Phase 1 Completed 12 enrolled National Atomic Research Institute, Taiwan
NaSingle-groupOpen-labelDiagnostic

Summary

This is a phase 1 study to evaluate the safety of Ga68-Dolacga Injection in healthy volunteers and to assess the normal reference range and inter-individual variability of the Ga68-Dolacga Injection in estimating liver reserve in healthy volunteers.

Timeline

Start
2019-02-12
Primary completion
2019-08-09
Completion
2019-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ga68-Dolacga Injection Diagnostic / imaging agent 3.5 mbq Intravenous

Indications

No indication recorded.